WO2008063671A3 - Heterobicyclic metalloprotease inhibitors - Google Patents

Heterobicyclic metalloprotease inhibitors Download PDF

Info

Publication number
WO2008063671A3
WO2008063671A3 PCT/US2007/024368 US2007024368W WO2008063671A3 WO 2008063671 A3 WO2008063671 A3 WO 2008063671A3 US 2007024368 W US2007024368 W US 2007024368W WO 2008063671 A3 WO2008063671 A3 WO 2008063671A3
Authority
WO
WIPO (PCT)
Prior art keywords
heterobicyclic
metalloprotease inhibitors
heterobicyclic metalloprotease
metalloprotease
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/024368
Other languages
French (fr)
Other versions
WO2008063671A2 (en
Inventor
Bert Nolte
Irving Sucholeiki
Tim Feuerstein
Jr Brian M Gallagher
Xinyuan Wu
Christoph Steeneck
Christian Gege
Hongbo Deng
Veldhuizen Joshua Van
Arthur Taveras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alantos Pharmaceuticals Holding Inc
Original Assignee
Alantos Pharmaceuticals Holding Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alantos Pharmaceuticals Holding Inc filed Critical Alantos Pharmaceuticals Holding Inc
Priority to AU2007321924A priority Critical patent/AU2007321924A1/en
Priority to CA002670083A priority patent/CA2670083A1/en
Priority to EP07862212A priority patent/EP2102211A2/en
Publication of WO2008063671A2 publication Critical patent/WO2008063671A2/en
Publication of WO2008063671A3 publication Critical patent/WO2008063671A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates generally to heterobicyclic containing pharmaceutical agents, and in particular, to heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic metalloprotease inhibiting compounds that exhibit an increased potency in relation to currently known metalloprotease inhibitors.
PCT/US2007/024368 2006-11-20 2007-11-20 Heterobicyclic metalloprotease inhibitors Ceased WO2008063671A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2007321924A AU2007321924A1 (en) 2006-11-20 2007-11-20 Heterobicyclic metalloprotease inhibitors
CA002670083A CA2670083A1 (en) 2006-11-20 2007-11-20 Heterobicyclic metalloprotease inhibitors
EP07862212A EP2102211A2 (en) 2006-11-20 2007-11-20 Heterobicyclic metalloprotease inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86019406P 2006-11-20 2006-11-20
US60/860,194 2006-11-20

Publications (2)

Publication Number Publication Date
WO2008063671A2 WO2008063671A2 (en) 2008-05-29
WO2008063671A3 true WO2008063671A3 (en) 2008-12-11

Family

ID=39272733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/024368 Ceased WO2008063671A2 (en) 2006-11-20 2007-11-20 Heterobicyclic metalloprotease inhibitors

Country Status (5)

Country Link
US (1) US20080176870A1 (en)
EP (1) EP2102211A2 (en)
AU (1) AU2007321924A1 (en)
CA (1) CA2670083A1 (en)
WO (1) WO2008063671A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637526B2 (en) 2008-10-31 2014-01-28 Genentech, Inc. Pyrazolopyrimidine JAK inhibitor compounds and methods
US9346815B2 (en) 2014-05-23 2016-05-24 Genentech, Inc. 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof
US10307426B2 (en) 2017-05-22 2019-06-04 Genentech, Inc. Therapeutic compounds and compositions, and methods of use thereof

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2670031A1 (en) * 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
EP2591675A1 (en) * 2006-11-27 2013-05-15 H. Lundbeck A/S Heteroaryl amide derivatives
JP2010520293A (en) * 2007-03-07 2010-06-10 アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド Metalloprotease inhibitors containing heterocyclic moieties
US8461163B2 (en) 2008-03-31 2013-06-11 Takeda Pharmaceutical Company Limited Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1
WO2010016584A1 (en) * 2008-08-07 2010-02-11 杏林製薬株式会社 Process for production of bicyclo[2.2.2]octylamine derivative
WO2010085246A1 (en) * 2009-01-21 2010-07-29 Praecis Pharmaceuticals Inc 2,4-diamino-1,3,5-triazine and 4, 6-diamino-pyrimidine derivatives and their use as aggrecanase inhibitors
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
CN110003219A (en) * 2010-07-13 2019-07-12 弗·哈夫曼-拉罗切有限公司 Pyrazolo [1,5A] pyrimidine and thieno [3,2B] pyrimidine derivatives as IRAK4 regulator
EP3366688B1 (en) 2010-12-08 2022-02-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Substituted pyrazolopyrimidines as glucocerebrosidase activators
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
WO2013059245A1 (en) 2011-10-17 2013-04-25 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
JP2015512913A (en) 2012-03-28 2015-04-30 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Salicylic acid derivatives useful as glucocerebrosidase activators
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oxetan-3-yl)piperazine-1-carbonyl)piperidin-1-yl)pyridin-3-yl)pyrazolo(1,5alpha)pyrimidine-3-carboxamide as inhibitor of atr kinase
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
PT3077397T (en) 2013-12-06 2020-01-22 Vertex Pharma 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
SG11201607895PA (en) * 2014-05-28 2016-12-29 Novartis Ag Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
MX373102B (en) 2014-06-05 2020-04-17 Vertex Pharma Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
EP4406616A3 (en) 2014-11-06 2024-11-06 Bial-R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
US20170333435A1 (en) 2014-11-06 2017-11-23 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
US20180185368A1 (en) 2014-11-06 2018-07-05 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
JO3637B1 (en) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc Rsv antiviral pyrazolo- and triazolo-pyrimidine compounds
CN106278895B (en) * 2015-05-15 2021-07-09 Dic株式会社 Carboxylic acid compound, method for producing the same, and liquid crystal composition using the compound
CN105085279A (en) * 2015-08-26 2015-11-25 吴玲 Preparation of R-5-chloro-1-aminoindane
CN105037169A (en) * 2015-08-26 2015-11-11 吴玲 Method for preparing S-5-chloro-1-aminoindane
CN105037168A (en) * 2015-08-31 2015-11-11 吴玲 Preparation of S-5-bromo-1-aminoindane by resolution of D-tartaric acid
CN105130824A (en) * 2015-08-31 2015-12-09 吴玲 Method for preparing S-5-bromo-1-aminoindane
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
EP3440081A4 (en) * 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
CA3020305A1 (en) 2016-04-06 2017-10-12 Lysosomal Therapeutics Inc. Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
AU2017246455B2 (en) 2016-04-06 2021-09-30 Bial - R&D Investments, S.A. Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
AU2017251155B2 (en) * 2016-04-15 2021-08-05 Elanco Animal Health Gmbh Pyrazolopyrimidine derivatives
WO2017192931A1 (en) 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO[1,2-α]PYRIDINES, SUBSTITUTED IMIDAZO[1,2-α]PYRAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
KR102530515B1 (en) 2016-05-05 2023-05-09 비알 - 알&디 인베스트먼츠, 에스.에이. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
MX2019001918A (en) 2016-08-15 2019-09-06 Bayer Cropscience Ag Condensed bicyclic heterocycle derivatives as pest control agents.
JP6832430B2 (en) 2016-08-31 2021-02-24 アジオス ファーマシューティカルズ， インコーポレイテッド Inhibitors of cell metabolism
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15 PGDH INHIBITORS WITH CORTICOSTEROIDS AND / OR TNF INHIBITORS AND USES THEREOF
JP2020514323A (en) * 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ Compositions and methods for modulating short chain dehydrogenase activity
SI3658557T1 (en) 2017-07-28 2024-10-30 Takeda Pharmaceutical Company Limited TYK2 inhibitors and their use
TW201932470A (en) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 Pyrazolopyrimidines having activity against RSV
SG11202006141RA (en) 2018-01-31 2020-07-29 Janssen Sciences Ireland Unlimited Co Cycloalkyl substituted pyrazolopyrimidines having activity against rsv
US11708369B2 (en) 2018-04-23 2023-07-25 Janssen Sciences Ireland Unlimited Company Heteroaromatic compounds having activity against RSV
CA3107621A1 (en) * 2018-07-25 2020-01-30 Avixgen Inc. Pharmaceutical composition for preventing, alleviating or treating osteoarthritis, containing rhodanine derivative as active ingredient
KR102921276B1 (en) 2018-11-21 2026-02-03 케이스 웨스턴 리저브 유니버시티 Compositions and methods for modulating short-chain dehydrogenase activity
CN111333548B (en) * 2020-04-10 2022-04-26 江苏海悦康医药科技有限公司 Preparation method of 1-(2-fluoro-6-(trifluoromethyl)benzyl)urea
CN111620881B (en) * 2020-07-08 2023-03-31 浙江合聚生物医药有限公司 Raatinib derivative and preparation method and application thereof
MX2024001294A (en) 2021-08-03 2024-02-13 Cytokinetics Inc Process for preparing aficamten.
EP4447971A4 (en) * 2021-12-17 2025-12-10 Merck Sharp & Dohme Llc Pyrazolopyrimid derivatives and methods for using them for the treatment of herpesviruses

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10148903A (en) * 1996-11-20 1998-06-02 Konica Corp Silver halide photographic sensitive material improved in pressure resistance
WO2002064595A1 (en) * 2001-02-14 2002-08-22 Warner-Lambert Company Llc Triazolo compounds as mmp inhibitors
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
EP1505068A1 (en) * 2002-04-23 2005-02-09 Shionogi & Co., Ltd. PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
WO2006083454A1 (en) * 2004-12-31 2006-08-10 Alantos Pharmaceuticals, Inc. Multicyclic bis-amide mmp inhibitors
WO2006128184A2 (en) * 2005-05-20 2006-11-30 Alantos-Pharmaceuticals, Inc. Pyrimidine or triazine fused bicyclic metalloprotease inhibitors
WO2007139856A2 (en) * 2006-05-22 2007-12-06 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10148903A (en) * 1996-11-20 1998-06-02 Konica Corp Silver halide photographic sensitive material improved in pressure resistance
WO2002064595A1 (en) * 2001-02-14 2002-08-22 Warner-Lambert Company Llc Triazolo compounds as mmp inhibitors
EP1505068A1 (en) * 2002-04-23 2005-02-09 Shionogi & Co., Ltd. PYRAZOLO (1,5-a) PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
WO2004087707A1 (en) * 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
WO2006083454A1 (en) * 2004-12-31 2006-08-10 Alantos Pharmaceuticals, Inc. Multicyclic bis-amide mmp inhibitors
WO2006128184A2 (en) * 2005-05-20 2006-11-30 Alantos-Pharmaceuticals, Inc. Pyrimidine or triazine fused bicyclic metalloprotease inhibitors
WO2007139856A2 (en) * 2006-05-22 2007-12-06 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8637526B2 (en) 2008-10-31 2014-01-28 Genentech, Inc. Pyrazolopyrimidine JAK inhibitor compounds and methods
US9346815B2 (en) 2014-05-23 2016-05-24 Genentech, Inc. 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof
US9604984B2 (en) 2014-05-23 2017-03-28 Genentech, Inc. 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof
US10307426B2 (en) 2017-05-22 2019-06-04 Genentech, Inc. Therapeutic compounds and compositions, and methods of use thereof

Also Published As

Publication number Publication date
CA2670083A1 (en) 2008-05-29
EP2102211A2 (en) 2009-09-23
WO2008063671A2 (en) 2008-05-29
AU2007321924A1 (en) 2008-05-29
US20080176870A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
WO2008063671A3 (en) Heterobicyclic metalloprotease inhibitors
WO2007139856A3 (en) Heterobicyclic metalloprotease inhibitors
WO2007139860A3 (en) Heterobicylic metalloprotease inhibitors
WO2008109177A3 (en) Metalloprotease inhibitors containing a heterocyclic moiety
WO2008002671A3 (en) Metalloprotease inhibitors
WO2006128184A3 (en) Pyrimidine or triazine fused bicyclic metalloprotease inhibitors
WO2008055068A3 (en) Inhibitors of histone deacetylase
TW200734315A (en) Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
TW200716119A (en) A solid pharmaceutical dosage formulation
WO2009082701A8 (en) Hcv protease inhibitors and uses thereof
MX2010006736A (en) Hcv protease inhibitors and uses thereof.
TW200610531A (en) Phthalazine derivatives as PARP inhibitors
IL187453A0 (en) The preparation and uses of compounds as aspartyl protease inhibitors
WO2006066133A3 (en) Histone deacetylase inhibitors
WO2008033798A3 (en) A pyrrolopyrazin as syk-kinase inhibitor
NO20074544L (en) Inhibition of HER2 release by matrix metalloprotease antagonists
IL181331A0 (en) Oxazolo-naphthyl acids as plasminogen activator inhibitor type i (pai-1) modulators
WO2008042480A3 (en) Epoxide inhibitors of cysteine proteases
AU2008203254A1 (en) Compositions of phosphodiesterase type IV inhibitors
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
AU2007337830A8 (en) Benzenesulfonamide derivatives as HIV protease inhibitors
EA200970164A1 (en) Caspase Inhibitors Based on Pyridasinone Carcass
WO2007044325A3 (en) Apoe4 domain interaction inhibitors and methods of use thereof
WO2010075086A3 (en) Pyrrolidinone inhibitors of pde-4
TW200621744A (en) Mercaptoamides as histone deacetylase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07862212

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2670083

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007321924

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2007321924

Country of ref document: AU

Date of ref document: 20071120

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007862212

Country of ref document: EP